Zoladex Related Published Studies
Well-designed clinical trials related to Zoladex (Goserelin)
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for
premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. [2012]
Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. [2011.04]
Randomized comparison of goserelin versus suction curettage prior to Thermachoice II balloon endometrial ablation: one-year results. [2010.10]
Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. [2009.03.04]
A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. [2007.11]
Goserelin Acetate 10.8 mg Plus Iron Versus Iron Monotherapy Prior to Surgery in Premenopausal Women with Iron-Deficiency Anemia Due to Uterine Leiomyomas: Results from a Phase III, Randomized, Multicenter, Double-Blind, Controlled Trial. [2007.08]
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. [2007.01.20]
Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial. [2006.12]
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). [2006.08]
Administration of goserelin acetate after uterine artery embolization does not change the reduction rate and volume of uterine myomas. [2006.05]
[Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B] [2005.12]
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. [2005.02.14]
Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. [2004.12]
European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. [2004.12]
Comparative study of different dosages of goserelin in size reduction of myomatous uteri. [2004.11]
The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. [2004.01]
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. [2003.12.17]
Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. [2003.12.15]
Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study. [2003.10]
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. [2003.08]
A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. [2003.06]
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. [2002.12.15]
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. [2002.11]
[A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies] [2002.09]
Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. [2002.08]
Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response. [2002.07]
A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion. [2001.05]
Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a 3-year follow-up evaluation. [2001.03]
A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. [2000.12]
Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group. [2000.02]
[Treatment of pelvic endometriosis with goserelin acetate or nafarelin acetate. Comparative study] [2000.01]
Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms. [2000]
Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group. [1999.11]
Goserelin acetate to avoid hysterectomy in pre-menopausal women with fibroids requiring surgery. [1999.11]
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. [1999.07.01]
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. [1999.07]
Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer. [1999.02.01]
The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study. [1999.02]
Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. [1999]
Comparison of goserelin and leuprolide in combined androgen blockade therapy. [1998.07]
Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. [1998.06]
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. [1998.03]
Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. [1998.01]
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. [1997.07.31]
Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study. [1997.07]
Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. [1997.03]
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. [1997.03]
Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. [1997.01]
Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. [1996.12]
The degree of fluid absorption during hysteroscopic surgery in patients pretreated with goserelin. [1996.08]
Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. [1996.08]
A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer. [1996.04]
A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation. [1996.04]
Depot goserelin and danazol pre-treatment before rollerball endometrial ablation for menorrhagia. [1996.04]
A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. [1996]
The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group. [1996]
An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism. [1996]
Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. [1995.11]
Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. [1995.09]
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. [1995.08]
Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction. [1995.04]
[Bromocryptin + gonadotropin vs. goserelin + gonadotropin in ovulation induction in patients with polycystic ovaries] [1995.03]
A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group. [1995]
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. [1995]
A Prospective Randomized Trial Comparing a GnRH Analog, Zoladex, and Danazol as Agents for Priming the Endometrium Prior to Endometrial Laser Ablation [1994.08]
Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. [1994.06]
Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids. [1994.05]
Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. [1994.04]
Role of goserelin-depot in the clinical management of uterine fibroids. [1994]
Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. [1993.12.15]
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853. [1993.12.15]
Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group. [1993.12.15]
Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study. [1993.12]
Estrogenic suppression by different administration schedules of goserelin depot for treatment of endometriosis. [1993.11]
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. [1993.08]
Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group. [1993.08]
Endocrine changes and follicular development in patients during ovulation induction using Goserelin and different gonadotropin treatments. [1993]
Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. [1993]
[Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate] [1992.10]
An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team. [1992.08]
Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin). [1992.06]
Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. [1992.06]
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. [1991.11]
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study. [1991.10]
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. [1991.05]
Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. [1991.02.06]
Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. [1991.01]
A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial. [1991]
Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853). [1990.12.20]
Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis. [1990.10]
The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis. [1990.10]
Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot. [1990.10]
Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. [1990.09.01]
Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group. [1990.09.01]
Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/month. [1990.03]
Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. [1990]
Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA). [1990]
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP). [1990]
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group. [1990]
Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. [1989.05]
A multi-centre randomised study to compare the effects of ovarian ablation with Zoladex depot in pre- and perimenopausal patients with advanced breast cancer. [1989]
|
